deCODE Genetics has shown how a single variant in the genome sequence leads to nicotine dependence and risk of lung cancer and other smoking related disease.
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases.
Their population approach and resources has enabled deCODE to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease.
The company is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics.
For more information on their findings visit http://www.decode.com/News/2008_04_02.php